Systematic review shows personalized tigecycline dosing improves outcomes in drug-resistant infections, indicating effective individualized therapy.
Based on the existing evidence, it is recommended to use high-dose tigecycline (100mg, q12h) for drug-resistant bacterial infections, cSSI and VAP, and consider combination therapy. Individualized dose adjustment should be based on liver function and the degree of drug resistance of the pathogen, without considering renal function. The application of other covariates and the model needs to be further verified.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: